-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2344 The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

Program: Oral and Poster Abstracts
Session: 902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I
Hematology Disease Topics & Pathways:
Diversity, Equity, and Inclusion (DEI)
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Aroog Khaliq1*, William Wesson, MPH2, Emerson Logan2*, Carine Tabak2*, Aliya Rashid, DO, MPH2, Razan Mansour3*, Muhammad Umair Mushtaq, MD4,5, Joseph P McGuirk, DO4, Hamza Hashmi, MD5,6*, Mehdi Hamadani, MD7, Al-Ola Abdallah, MD5,8 and Nausheen Ahmed, MD5,8,9

1University of Kansas School of Medicine, Overland Park, KS
2University of Kansas School of Medicine, Kansas City, KS
3Internal Medicine, University of Kansas Medical Center, Kansas City, KS
4University of Kansas Medical Center, Westwood, KS
5US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
6Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
7Division of Hematology and Oncology, The Medical College of Wisconsin Inc, Milwaukee, WI
8Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
9The University of Kansas Cancer Center, Westwood, KS

Introduction: Existing literature suggests that women are significantly underrepresented in the field of hematology-oncology. Data from 2021 suggests that women make up 35.6% of hematologists, and thus the disparity continues in clinical trial research authorship. Minorities including women receive fewer awards, deliver fewer board review lectures, and hold fewer professorships, and leadership positions in clinical departments and professional organizations. To further investigate this issue, we conducted a study to assess the gender gap in authorship across 13 pivotal clinical trials that led to the approval of CD19 and BCMA Chimeric antigen receptor T cell (CAR-T) therapies.

Methods: We included the 13 pivotal trials that led to the approval of CART for Acute Lymphoblastic leukemia (ALL), lymphoma and myeloma , published between 2017-2022. These included the trials: ELIANA, ZUMA-1, JULIET, ZUMA-2, KarMMa, TRANSCEND, ZUMA-5, CARTITUDE-1, ZUMA-7, ZUMA-3, TRANSFORM, PILOT, and ELARA.

We examined the overall number of female authors, the number of lead female authors as defined as first, second, or last author, and the ratio of all authors to female authors. 367 total authors were included in the analysis, with several authors being included more than once for their work on separate studies.

Results: Table 1 summarizes the results. Of the 367 authors assessed, 109 were female, correlating to 28.9% female authorship. The only study with female authorship >50% was ELIANA, a 2017 pediatric study, while all others had >50% male authorship. 7 (54%) of the 13 studies had females as lead authors; of note, 6 out of 7 of these studies were published after 2021.

Conclusion: Gender inequities in research authorship are pervasive in many areas of medicine, including the field of immune effector cell therapy. Publications in the field broadly are overwhelmingly male dominated, possibly reflective of lower female representation in transplant and cellular therapy. Despite this, we observed improved gender equality in authorship in more recent publications since 2021, and in certain research areas such as pediatric hematology-oncology. Recognizing these seemingly invisible barriers is the first step in bringing gender equity to the field of hematopoietic stem cell transplant and cellular therapy, with gender serving as one of many domains in which underrepresented groups’ ability to scale the glass wall must be supported.

Table 1.

Disclosures: McGuirk: EcoR1 Capital: Consultancy; Pluristem Therapeutics: Research Funding; Kite: Consultancy, Research Funding; Juno Therapeutics: Consultancy; Fresenius Biotech: Research Funding; Astellas Pharma: Research Funding; Bellicum Pharmaceuticals: Research Funding; Novartis: Research Funding; Magenta Therapeutics: Consultancy; Allovir: Consultancy, Research Funding; Gamida Cell: Research Funding. Hashmi: GSK: Honoraria, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau; Karyopharm: Speakers Bureau; BMS: Honoraria; Jannsen: Honoraria, Speakers Bureau. Hamadani: ADC therapeutics: Consultancy, Honoraria, Research Funding, Speakers Bureau; Incyte: Consultancy; Gamida Cell: Consultancy; Genmab: Consultancy; Kite, a Gilead Company: Consultancy, Speakers Bureau; Abbvie: Consultancy; Genmab: Consultancy; Caribou: Consultancy; Bristol Myers Squibb: Consultancy; BeiGene: Speakers Bureau; AstraZeneca: Speakers Bureau; Kadmon: Consultancy; Legend Biotech: Consultancy; Omeros: Consultancy; CRISPR: Consultancy; MorphoSys: Consultancy; Genentech: Honoraria; Myeloid Therapeutics: Honoraria; Novartis: Consultancy; SeaGen: Consultancy; Astra Zeneca: Speakers Bureau; BeiGene: Speakers Bureau; Sanofi Genzyme: Speakers Bureau; Astellas: Research Funding; Spectrum Pharmaceuticals: Research Funding; Takeda: Research Funding. Ahmed: Bristol Myers Squibb: Consultancy; Kite, a Gilead company: Research Funding.

*signifies non-member of ASH